Patents by Inventor Mathieu UZZAN

Mathieu UZZAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE
    Publication number: 20220098665
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drag response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Application
    Filed: June 7, 2021
    Publication date: March 31, 2022
    Inventors: Eric OGIER-DENIS, Xavier TRETON, Yoram BOUHNIK, Ian MORILLA, David LAHARIE, Gilles WAINRIB, Mathieu UZZAN
  • Methods for predicting acute severe colitis treatment response
    Patent number: 11060147
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPPITAUX DE PARIS (APHP), UNIVERSITE DE BORDEAUX, CHU DE BORDEAUX, UNIVERSITE PARIS XIII PARIS-NORD
    Inventors: Eric Ogier-Denis, Xavier Treton, Yoram Bouhnik, Ian Morilla, David Laharie, Gilles Wainrib, Mathieu Uzzan
  • METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE
    Publication number: 20190136324
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Application
    Filed: June 14, 2017
    Publication date: May 9, 2019
    Inventors: Eric OGIER-DENIS, Xavier TRETON, Yoram BOUHNIK, Ian MORILLA, David LAHARIE, Gilles WAINRIB, Mathieu UZZAN